Effects of two instrument-generation changes on adenoma detection rate during screening colonoscopy: results from a prospective randomized comparative study

Endoscopy. 2018 Sep;50(9):878-885. doi: 10.1055/a-0607-2636. Epub 2018 Jul 23.

Abstract

Background: Previous studies have shown that multiple colonoscope features have to be changed before an improvement in adenoma detection rate (ADR) becomes obvious, such as with changing from one instrument generation to the next but one. We wanted to evaluate whether such an effect can also be observed in a private-practice screening setting.

Methods: In a randomized study, we compared the latest generation colonoscopes from one company (Olympus Exera III, 190) with the next to last one (Olympus 165), including only patients presenting for screening colonoscopy. The primary outcome was ADR achieved with 190 colonoscopes (190-C) in comparison with 165 colonoscopes (165-C).

Results: 1221 patients (46.1 % men; mean age 62.2 years, standard deviation 6.6) were included (599 screened with the Olympus Exera III, 190). The ADR difference in favor of the 190-C instrument (32 % [95 % confidence interval (CI) 26 % to 39 %] vs. 28 % [95 %CI 22 % to 34 %] in the 165-C group) failed to reach statistical significance (P = 0.10); only the rate of small (< 5 mm) adenomas was significantly increased at 22.5 % (95 %CI 19 % to 26 %) vs. 15.6 % (95 %CI 13 % to 18 %; P = 0.002). Furthermore, significantly more adenomas were found in the 190-C group, with an adenoma rate (all adenomas/all patients) of 0.57 (95 %CI 0.53 to 0.61) vs. 0.47 (95 %CI 0.43 to 0.51; P < 0.001).

Conclusions: This randomized comparative trial in a private-practice screening setting only partially confirmed the results of prior studies that, with multiple imaging improvements achieved over two instrument generations, an increase in overall adenoma number becomes measurable.

Trial registration: ClinicalTrials.gov NCT03137277.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adenoma / diagnosis*
  • Adenoma / pathology
  • Aged
  • Colonoscopes / standards*
  • Colonoscopy* / instrumentation
  • Colonoscopy* / methods
  • Colorectal Neoplasms / diagnosis*
  • Colorectal Neoplasms / pathology
  • Equipment Design*
  • Female
  • Germany
  • Humans
  • Male
  • Mass Screening / instrumentation
  • Mass Screening / methods
  • Materials Testing* / methods
  • Materials Testing* / statistics & numerical data
  • Middle Aged
  • Outcome Assessment, Health Care
  • Quality Improvement

Associated data

  • ClinicalTrials.gov/NCT03137277